fashion -WSS

fashion

author：focus 2025-09-27 09:55:03 - browse：42173

Photograph of a person wearing blue gloves counts money. -- health business coverage from STAT — Adobe

WASHINGTON — Doctors are staring down a cut to their Medicare pay next year, and while the news has united them in outrage, it’s also turned one specialty against another.

Medicare officials last week announced its major annual update to the way the program pays physicians. Along with other changes, it includes a policy that will boost payments to specialties that rely on evaluating and managing patients, as opposed to those that focus on procedures. But in Medicare, boosting payments in one area almost always means cutting them somewhere else. So to pay for that, doctors across the country will see a roughly 3% cut to a factor that determines how much Medicare pays them for caring for seniors.

The change has pitted certain specialties against primary care doctors. A host of surgeons’ groups, including the American College of Surgeons, plainly criticized family physicians in a recent letter to Medicare, saying there’s no “valid justification” for the boost and calling it an “inappropriate” overpayment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： EF3 tornado rips through North Carolina amid extreme weather nationwide

leisure time

WSS

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Tocagen's brain cancer gene therapy trial continues. Investors worry

Stanford president's case begs question: Who takes blame?

Can sheer will power keep patients alive in their dying hours?

Prime Medicine, Myeloid Therapeutics clash over genome

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

explore

fashion

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Three trends to watch in biotech in 2024

The cancer drug shortage isn’t new — and neither are the solutions

Editas, Vertex strike deal on CRISPR

Apple is now the first public company to be valued at $3 trillion

Indian pharmaceutical industry in denial over drug

Psychedelics group wrestles with new pharma identity

Medicare drug price negotiation hasn't dried up venture capital

Peter Hotez and the public health issue of online harassment

Readout Newsletter: The latest on Moderna, Apellis, and Merck

hotspot

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Grail spinoff by Illumina should end disastrous merger attempt

Tocagen's brain cancer gene therapy trial continues. Investors worry

Christmas in the PICU brings some surprising joy

Stanford president faces new allegations over 1999 paper

Mass General totes up its waste in a move to tackle climate change

explore

leisure time

Wikipedia

entertainment